0001493152-23-025139.txt : 20230721 0001493152-23-025139.hdr.sgml : 20230721 20230720181011 ACCESSION NUMBER: 0001493152-23-025139 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230721 DATE AS OF CHANGE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-255544 FILM NUMBER: 231100696 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 424B3 1 form424b3.htm

PROSPECTUS SUPPLEMENT

(To Prospectus dated April 27, 2021)

Filed Pursuant to Rule 424(b)(3)

Registration No. 333- 255544

Biotricity, Inc.

Up to $8,277,159

Common Stock

This prospectus supplement amends and supplements the information in the prospectus, dated April 27, 2021, filed as a part of our registration statement on Form S-3 (File No. 333-255544), as supplemented by our prospectus supplement dated March 22, 2022, or the Prior Prospectus. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, or the Sales Agreement, between H.C. Wainwright & Co., LLC, or Wainwright, acting as the agent, and us. Through the date hereof, we have not sold any shares of common stock under the Sales Agreement pursuant to the Prior Prospectus.

We are filing this prospectus supplement to amend the Prior Prospectus to update the amount of shares we are eligible to sell under General Instruction I.B.6. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $8,277,159 from time to time through Wainwright.

As of July 19, 2023, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was $24,831,477, which was calculated based on 7,593,724 shares of our outstanding common stock held by non-affiliates at a price of $3.27 per share, the closing price of our common stock on July 3, 2023. During the 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3.

Our common stock is quoted on The Nasdaq Capital Market under the symbol “BTCY.” On July 18, 2023, the last reported sale price of our common stock was $3.00 per share.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

H.C. Wainwright & Co.

The date of this prospectus supplement is July 20, 2023